Clin2
NCT06684327Possibly a fitRecruiting

Study of three chemotherapy drugs for rare advanced cancers

Paget Disease, ExtramammaryRhabdomyosarcomaTesticular CancerPenile CancerUrachal Cancer

Treatments studied

Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.

This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these rare cancers: Paget's disease of the scrotum with sweat gland cancer, rhabdomyosarcoma, testicular cancer, penile cancer, or urachal cancer.
  • Your cancer has spread to other parts of the body (stage IV).
  • You are well enough to be on your feet and care for yourself (ECOG score 0-2).
  • You have at least 3 months to live, as estimated by your doctor.
  • Your cancer can be measured on a CT or MRI scan, or has skin sores that can be seen and measured.
  • Your blood counts, liver, kidney, and clotting function are within adequate levels (no need for transfusions).
  • You agree to use effective birth control during and for 4 months after treatment, and not to donate sperm.
  • You have not had major surgery or injury in the last 28 days, and you do not have serious infections, active hepatitis, HIV, or organ transplant history.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06683846Recruiting· Phase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study

This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.

Shanghai, Shanghai Municipality
NCT06791070Recruiting· Phase 2
RC48-ADC plus immunotherapy for advanced scrotal Paget disease

This trial tests a combination of two drugs (RC48-ADC and JS001) for advanced scrotal Paget disease that has spread or cannot be removed by surgery. The goal is to see if this treatment can help shrink or control the cancer.

Fuzhou, Fujian
NCT06353906Recruiting· Phase 2
Chemo plus immunotherapy for advanced penile cancer

This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.

Leuven
NCT06415318Recruiting· Phase 2
TIP chemo plus triplizumab before surgery for penile cancer

This trial tests a combination of chemotherapy drugs (paclitaxel, ifosfamide, cisplatin) and an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor and improve outcomes.

Guangzhou, Guangdong
NCT07046650Recruiting· Phase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy

This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.

Shanghai, Shanghai Municipality
NCT06391190Recruiting· Phase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer

This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.

Shanghai

Hear when a new Paget Disease, Extramammary trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.